home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

295 rows where filing_period = "third_quarter", filing_year = 2020 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 295 ✖

filing_year 1

  • 2020 · 295 ✖

filing_period 1

  • third_quarter · 295 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2503881 HOLLAND & KNIGHT LLP 25bcf25e-e2fc-47a9-afb4-e1074837f16b Q3 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2020 third_quarter PHA Drug shortages, formulary tiering, National Defense Authorization Act (NDAA), biosimilar uptake, Medicare generics penalty, generic drugs, supply chain. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-05T10:52:24.070000-04:00
2503982 WATKINS & EAGER PLLC 12c11c87-aa4b-4691-95fb-80172ab11942 Q3 WATKINS & EAGER PLLC 401104403 ZYNERBA PHARMACEUTICALS, INC. 2020 third_quarter PHA Support Zynerba and its partners, and any other of its contractors in its process before the FDA; Troubleshoot inevitable issues and eligibility hurdles to ensure the project is considered for approval; Brief staff of FDA throughout process to ensure they have all information needed; Work with Zynerba to formulate the best strategy to work with FDA in preparation for any scheduled meetings. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-10-05T13:28:00.437000-04:00
2504097 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 90e37133-7139-4887-a5a5-debd936fafed Q3 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2020 third_quarter PHA Drug pricing, 340B for children's hospitals Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   35404 0 0 2020-10-05T16:33:48.187000-04:00
2504191 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 4d31ac54-0cb2-4c61-9b68-ecf507f5d576 Q3 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2020 third_quarter PHA Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2020-10-06T10:10:34.017000-04:00
2504232 RUBICON ADVISORS, LLC dfe6398e-03fc-4b41-9239-007395f97e88 Q3 RUBICON ADVISORS, LLC 315091 ASCENDIS PHARMA, INC. 2020 third_quarter PHA Food and Drug Administration, Orphan Drugs Food & Drug Administration (FDA) 60000   0 0 2020-10-06T11:10:58.677000-04:00
2504238 RUBICON ADVISORS, LLC 9b7e35d9-bc2c-4656-90bf-3ec86f407a91 Q3 RUBICON ADVISORS, LLC 315091 AVET PHARMACEUTICALS 2020 third_quarter PHA GENERIC DRUG PRICING,HOUSE COMMITTEE ON OVERSIGHT,GOVERNMENT REFORM, FOOD AND DRUG ADMINISTRATION AND COVID-19 DRUG SHORTAGES Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES 30000   0 0 2020-10-06T11:18:02.390000-04:00
2504240 TODD STRATEGY GROUP 2b1b1dac-444f-4459-a719-959ad13a4aaf Q3 TODD STRATEGY GROUP 401103321 ALKERMES, INC. 2020 third_quarter PHA Prescription drug pricing. C.R.8337: Continuing Appropriations Act, 2021. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-06T11:20:04.713000-04:00
2504243 RUBICON ADVISORS, LLC 13f7372f-7f9b-40b4-a44c-c384753fa4ae Q3 RUBICON ADVISORS, LLC 315091 CONSCIOUS DISCIPLINE 2020 third_quarter PHA Medicare HOUSE OF REPRESENTATIVES,SENATE 37500   0 0 2020-10-06T11:22:06.687000-04:00
2504246 RUBICON ADVISORS, LLC 7af872d3-e3eb-48d0-9ccb-fd16bd792b69 Q3 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2020 third_quarter PHA Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 45000   0 0 2020-10-06T11:27:08.170000-04:00
2504265 RUBICON ADVISORS, LLC b88e8417-3272-4682-b354-f33920e273e3 Q3 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2020 third_quarter PHA Prescription Drug User Fee, Biomedical Advance Research and Development Authority (BARDA) HOUSE OF REPRESENTATIVES,SENATE 75000   0 0 2020-10-06T11:50:17.690000-04:00
2504268 TODD STRATEGY GROUP 7735c51e-3378-479f-8d4b-984a76f8be6f Q3 TODD STRATEGY GROUP 401103321 BIOTECHNOLOGY INNOVATION ORGANIZATION 2020 third_quarter PHA Drug Pricing and Access. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-10-06T11:53:19.247000-04:00
2504271 TODD STRATEGY GROUP 5966d649-77d3-491e-bd80-e4c4f1aae79e Q3 TODD STRATEGY GROUP 401103321 CAREDX, INC. 2020 third_quarter PHA Coverage of immunosuppressive drugs. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 40000   0 0 2020-10-06T11:54:20.623000-04:00
2504274 RUBICON ADVISORS, LLC ac4d4ce0-f6c3-4c1e-9945-15219a95a955 Q3 RUBICON ADVISORS, LLC 315091 LANNETT COMPANY, INC 2020 third_quarter PHA Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 60000   0 0 2020-10-06T11:55:22.863000-04:00
2504279 TODD STRATEGY GROUP 4f70bfbb-39af-496e-bfc6-7a523fa6e6e8 Q3 TODD STRATEGY GROUP 401103321 EMD SERONO INC. 2020 third_quarter PHA Drug pricing policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-06T11:55:24.323000-04:00
2504289 RUBICON ADVISORS, LLC 791110e4-0878-4b73-9fb5-aa580fad1996 3T RUBICON ADVISORS, LLC 315091 PURE BLUE DIAGNOSTICS, A DIVISION OF PURE BLUE MEDICAL 2020 third_quarter PHA Food and Drug Administration, COVID-19 Testing Food & Drug Administration (FDA) 30000   0 1 2020-10-06T12:04:29.567000-04:00
2504300 TODD STRATEGY GROUP 18dfa396-679f-4a82-907f-7116557eaa77 Q3 TODD STRATEGY GROUP 401103321 US WORLDMEDS, LLC 2020 third_quarter PHA Opioid Use Disorder Treatment Policy. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-10-06T12:32:40.033000-04:00
2504482 THORSEN FRENCH ADVOCACY LLC 1afb379e-faa4-4588-92e3-040be3933698 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2020 third_quarter PHA General issues related to prescription drug abuse. Issues related to pharmaceutical market value. Prescription drug importation. Issues related to regulation of prescription opioid medication. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-06T17:52:10.787000-04:00
2504492 THORSEN FRENCH ADVOCACY LLC f51ea890-6356-471d-b6fb-84293324f741 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2020 third_quarter PHA Issues related to pharmaceutical market value. Global supply chain. Proposed Notice of Benefit and Payment Parameters (NBPP) Rule for 2021. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-10-06T17:59:15.687000-04:00
2504653 AMERICAN COLLEGE OF CLINICAL PHARMACY 0e14125c-af0d-4f2a-855e-d1980d99bb1b Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2020 third_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2020-10-07T13:29:08.140000-04:00
2505222 ACG ADVOCACY 93217167-e4a2-4566-9920-a4ddc049d09a Q3 ACG ADVOCACY 2057 WALGREEN CO. 2020 third_quarter PHA Drug Pricing Policy Issues. Data privacy and DIR fee reform. Public Health Crisis. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-08T16:35:48-04:00
2505289 ACG ADVOCACY 28c01c46-667d-43fc-bd2f-d4269e42a097 Q3 ACG ADVOCACY 2057 LYNDRA THERAPEUTICS, INC. 2020 third_quarter PHA Issues related to advanced pharmaceutical and domestic supply chain. Health & Human Services, Dept of (HHS),White House Office 70000   0 0 2020-10-08T17:20:31.237000-04:00
2505424 PANNONE LOPES DEVEREAUX & O'GARA LLC 66f11261-2a9c-4763-af68-fedada2047f3 Q3 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2020 third_quarter PHA Prescription drug pricing.   9000   0 0 2020-10-09T10:05:11.183000-04:00
2505570 TAUZIN STRATEGIC NETWORKS 1f0d9f14-c1ab-4a15-943f-aff8a066af22 3T TAUZIN STRATEGIC NETWORKS 400786367 CAPTURERX 2020 third_quarter PHA Issues related to the 340b program HOUSE OF REPRESENTATIVES,SENATE     0 1 2020-10-09T12:09:02.527000-04:00
2505677 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION f5226059-fb54-4c6c-8462-a8e6bc7747a8 Q3 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 401103437 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2020 third_quarter PHA In-office Compounding Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-10-09T12:49:02.517000-04:00
2505996 RED+BLUE STRATEGIES d5f3a39f-f84e-4db7-a4c7-299acc27ab4d Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2020 third_quarter PHA Executive Orders and Regulations related to pharmacy issues including the creation of an international price index, a Medicare drug discount card and the Medicare rebate rule. H.R. 8406 - The HEROES ACT (modified) - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID-19 pandemic. Senate HEALS Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic. H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications. H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic. H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond. H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation- Issues related to supporting programs and institutions supporting during the current pandemic. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 60000   0 0 2020-10-11T20:58:02.540000-04:00
2506001 RED+BLUE STRATEGIES 6de10f5a-fea2-45ce-8d41-2b0c5a70d684 Q3 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2020 third_quarter PHA S. 4760 - Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act - Strategies to address problems related to treating currently antibiotic resistant diseases and infections. S. 6725 - The National Defense Authorization Act - Issues related to ensuring that there are antibiotics in the pipeline to ensure that our nation's troops are adequately protected from infection-related complications. H.R. 6800 - THe HEROES Act - Issues related to continuing the fight against SUD and opioid addiction in the time of COVID. Issues related to ensuring that there were new, effective antibiotics in the pipeline to treat secondary infections due to hospitalizations for COVID. Issues related to HIT as a tool during the pandemic. H.R. 748 - CARES Act - Implementation - Issues related to supporting the national work fighting COVID-19 and ensuring that antibiotics are available during the COVID-19 crisis and beyond and OTC monograph reform is address to enhance patient safety. H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting the public good with a focus on ensuring there is a strong antibiotics pipeline to fight secondary infections and over the counter medications are safe and secure. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation - Issues related to supporting programs and institutions supporting during the current pandemic. S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. Issues related to creating a listing mechanism for dietary supplements. Issues related to the implementation on the SUPPORT Act (P.L. 115-271) HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-10-11T21:07:04.037000-04:00
2506038 RED+BLUE STRATEGIES 570e38b7-8569-4600-ba8d-8a705f978f1f Q3 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2020 third_quarter PHA H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues. H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders. Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6800 - The HEROES Act - Issues related to lowering costs of prescription drugs for Americans. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public… Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-10-12T10:23:34.667000-04:00
2506277 KOUNTOUPES DENHAM CARR & REID, LLC cbdb09e1-fffd-4cbc-9d48-03f40e77a5c8 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) 2020 third_quarter PHA Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. Issues related to Presidential Executive Orders regarding drug pricing. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-12T15:26:14.697000-04:00
2506363 HOLLAND & KNIGHT LLP 56de192c-4e38-4b2c-856b-cf1d8f283e5e Q3 HOLLAND & KNIGHT LLP 18466 TEVA PHARMACEUTICALS USA, INC. 2020 third_quarter PHA Global supply chain issues; National Defense Authorization Act. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2020-10-12T17:49:16.380000-04:00
2506621 PARAGON BIOSCIENCES, LLC 570d47f5-2763-4858-a52b-b68353f7fb5f Q3 PARAGON BIOSCIENCES, LLC 401105338 PARAGON BIOSCIENCES, LLC 2020 third_quarter PHA Issues related to public and private investment in biosciences and R&D HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2020-10-13T11:25:03.227000-04:00
2506632 INDEPENDENT PHARMACY COOPERATIVE 6bc37521-3cf5-487d-b59b-7a9841ba24bf Q3 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2020 third_quarter PHA The Prescription Drug Pricing Reduction Act S. 2543-IPC supports. Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale. Support regulations that would eliminate pharmacy DIR. IPC supports Pharmacists as providers under Medicare Part B IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies First Families Coronavirus Response Act 2020. IPC supports The Coronavirus Aid, Relief and Economic Security Act 2020. IPC supports Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   30000 0 0 2020-10-13T11:34:14.607000-04:00
2506710 THE KUTLER GROUP bd9a7475-c311-4091-af34-a2c35b2c2b2e Q3 THE KUTLER GROUP 401103966 PRIME THERAPEUTICS 2020 third_quarter PHA drug pricing issues monitor Covid 19 legislation HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2020-10-13T12:18:15.017000-04:00
2506831 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 778a6351-3b8f-4939-a0c1-d643b64c02de Q3 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 30212 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2020 third_quarter PHA Drug pricing, Direct and Indirect remuneration fees, Medicare, COVID-19 Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2020-10-13T13:59:02.813000-04:00
2506980 BOLD STRATEGIES, LLC 1bac0306-16ea-4f78-a1dc-6664459610fa Q3 BOLD STRATEGIES, LLC 401104653 MORRIS & DICKSON CO., LLC 2020 third_quarter PHA Prescription drug issues generally. HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-10-13T15:25:13.163000-04:00
2507137 KOUNTOUPES DENHAM CARR & REID, LLC c91fc14d-5ada-445c-8190-c8e1b856018c Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2020 third_quarter PHA Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to the implementation of PL 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions. Issues related to H.R. 6800, the Heroes Act. Issues related to proposals that would address drug shortages and national stockpile issues. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-10-13T17:38:01.273000-04:00
2507365 TARPLIN, DOWNS & YOUNG, LLC 69e60df4-b158-43ae-9eb5-a1f813456ceb Q3 TARPLIN, DOWNS & YOUNG, LLC 304736 ASTRAZENECA 2020 third_quarter PHA Drug coverage & reimbursement no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay H.R. 3 - Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act S. 1895 - Lower Health Care Costs Act S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S. 3129 - Lower Costs, More Cures Act of 2019 Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-10-14T10:32:12.683000-04:00
2507386 TARPLIN, DOWNS & YOUNG, LLC ff703277-7849-4c35-aec0-7bfb9261defc Q3 TARPLIN, DOWNS & YOUNG, LLC 304736 BIOTECHNOLOGY INDUSTRY ORGANIZATION 2020 third_quarter PHA H.R. 1781 - Payment Commission Data Act of 2019 H.R. 938 - the BLOCKING Act of 2019 H.R. 1520 - the Purple Book Continuity Act of 2019 H.R. 1503 - the Orange Book Transparency Act of 2019 H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 H.R. 965 - the CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions For Patients Act of 2019 H.R. 3 - Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S. 3129 - Lower Costs, More Cures Act of 2019 no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 80000   0 0 2020-10-14T10:38:16.740000-04:00
2507503 KOUNTOUPES DENHAM CARR & REID, LLC d33eeb22-a071-42e3-86b6-e3026c1e2d04 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2020 third_quarter PHA General issues related to over the counter pharmaceuticals and pharmaceutical supply chain. Implementation of the Over the Counter Monograph provisions included in PL 116-136, Coronavirus Aid, Relief and Economic Security Act. Issues related to supplements. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-14T11:35:51.567000-04:00
2507589 SUMMIT PUBLIC AFFAIRS 36a6a35f-ffe8-41f6-ae89-05414a5a94a6 Q3 SUMMIT PUBLIC AFFAIRS 401105467 VANDA PHARMACEUTICALS INC. 2020 third_quarter PHA Issues affecting the pharmaceutical industry, including the prescription drug approval process, animal testing, and gastroparesis issues. Administration of the 21st Century Cares Act (Pub. L. No. 114-255). Administration of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (Pub. L. No. 116-136). COVID-19 Clinical Trials. H.R. 7608, Agriculture, Rural Development, FDA, and Related Agencies Appropriations for FY2021, provisions regarding FDA testing for new drug applications. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-10-14T12:44:23.780000-04:00
2507614 KOUNTOUPES DENHAM CARR & REID, LLC ed30b2ff-da64-4745-bf92-e39d11dc7b21 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2020 third_quarter PHA General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. Issues related to the implementation of H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including drug supply chain dynamics. H.R. 6800, the HEROES Act. S. Amdt 2652, the Targeted COVID Relief Package. Issues related to the federal response to the COVID-19 pandemic. Supply chain and essential medicine manufacturing. Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-14T13:06:35.537000-04:00
2508429 ROCK & ASSOCIATES 29e2e46e-0b2f-4ad8-b689-ad92576c9ded Q3 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2020 third_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2020-10-14T23:46:39.977000-04:00
2508432 ROCK & ASSOCIATES 0eb8e85f-0add-496c-b4b0-6c00882fecef Q3 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2020 third_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2020-10-14T23:47:40.643000-04:00
2508435 ROCK & ASSOCIATES 44bc882c-cc1b-4505-bb41-1b204662ca38 Q3 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2020 third_quarter PHA H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2020-10-14T23:48:41.220000-04:00
2508437 ROCK & ASSOCIATES d6aa502f-70d7-400c-bc99-0f8d6b7fc514 Q3 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2020 third_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2020-10-14T23:50:41.707000-04:00
2508442 ROCK & ASSOCIATES 3f03fb29-4bd7-4122-a632-bf1cccbcf418 Q3 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2020 third_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2020-10-14T23:51:42.397000-04:00
2508445 ROCK & ASSOCIATES 7856830a-045d-48c3-8cb4-604fb974bc12 Q3 ROCK & ASSOCIATES 33545 PRECISION PHARMACY 2020 third_quarter PHA H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2020-10-14T23:52:42.957000-04:00
2508576 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 7f7b549d-acc4-4c7a-b997-9051b75ee71a Q3 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2020 third_quarter PHA H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019; H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019; H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019; H.R. 5198, the Patients' Right to Know Their Medication Act of 2019; H.R. 5304, the PBM Transparency in Prescription Drug Costs Act; Draft Long Term Care pharmacy definition legislation Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   330000 0 0 2020-10-15T10:03:20.690000-04:00
2508583 WAXMAN STRATEGIES b726e06b-f5ff-4a18-9f81-db96b03a0cab Q3 WAXMAN STRATEGIES 401103693 340B HEALTH 2020 third_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-10-15T10:05:23.650000-04:00
2508670 WINNING STRATEGIES WASHINGTON 340381f4-4ce3-4e44-b70f-86a26d249765 Q3 WINNING STRATEGIES WASHINGTON 50796 KALEO 2020 third_quarter PHA Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-10-15T10:36:45.417000-04:00
2508678 NATIONAL RURAL HEALTH ASSOCATION 91b5f46a-4bb6-4bb2-a9b7-488a94a3ff32 Q3 NATIONAL RURAL HEALTH ASSOCATION 53048 NATIONAL RURAL HEALTH ASSOCATION 2020 third_quarter PHA The 340B Program and drug pricing Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE   29156 0 0 2020-10-15T10:36:47.620000-04:00
2508787 AARP cc0b42e8-1521-48f4-a2cc-ed4a9fe6cac8 Q3 AARP 1694 AARP 2020 third_quarter PHA S. 2543, the Prescription Drug Pricing Reduction Act. H.R. 7288, the Taxpayer Research and Coronavirus Knowledge (TRACK) Act. No bill number. Discussed COVID-19 vaccine development, approval, and distribution. No bill number. Discussed mail-order prescription drugs. H.R. 19/S. 3129, Lower Cost More Cures Act. H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act. Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Corporation for Natl & Community Service,Federal Communications Commission (FCC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Indian Health Service,Internal Revenue Service (IRS),Labor, Dept of (DOL),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Office of the Comptroller of the Currency (OCC),Pension Benefit Guaranty Corporation (PBGC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office   1880000 0 0 2020-10-15T11:03:12.777000-04:00
2509235 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 4e0e29fe-053b-44cc-9017-23b311c1ba76 Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2020 third_quarter PHA Pseudoephedrine -- Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient and oppose PSE restrictions such as a prescription requirement (no bill number). Mandatory recall authority of the FDA Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. H.R.3164 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 S.930 - Allowing Greater Access to Safe and Effective Contraception Act S.1847/H.R. 3296 - Affordability is Access Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.6058 - SHOP SAFE Act of 2020 S.3431 - INFORM Consumers Act Legislation to increase domestic production of pharmaceuticals and the domestic supply chain. H.R. 6395 - National Defense Authorization Act for Fiscal Year 2021 S.4049 - National Defense Authorization Act for Fiscal Year 2021 HR 8179 - Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 Commerce, Dept of (DOC),Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,Vice President of the U.S.   140000 0 0 2020-10-15T12:33:17.327000-04:00
2509823 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. fbd10f32-6de9-4a03-a2c4-eeb24ca276b5 Q3 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2020 third_quarter PHA Opioids; CREATES Act; Drug Pricing HR 5578 (116th Congress), Recall Unsafe Drugs Act of 2020, by Rep. Rosa DeLauro (D-CT). Provide for the mandatory recall of drugs regulated by the Food and Drug Administration. HR 5691 (116th Congress), Insulin Affordability Data Collection Act, by Rep. Angie Craig (D-MN). Require the Secretary to conduct a study and issue a report on the affordability of insulin. HR 5749 (116th Congress), Affordable Insulin for All Act, by Rep. Charlie Crist (D-FL). Establish the American Insulin Program to provide for lower prices for insulin drugs, to maintain effort throughout the insulin supply chain. HR 6193 (116th Congress), Medication Access in Emergencies Act of 2020, by Rep. Chris Pappas (D-NH). Require group health plans and health insurance issuers offering group or individual health insurance coverage to provide benefits under such plan or such coverage for a 30-day refill of prescription drugs to individuals who reside in emergency areas during emergency periods. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office   160000 0 0 2020-10-15T16:22:00.710000-04:00
2509827 LUNGREN LOPINA LLC 94261a95-6dbb-49e4-a1f6-876551daf93c Q3 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2020 third_quarter PHA Fair treatment for US based pharmaceutical ingredients HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-10-15T16:23:02.210000-04:00
2510008 POLSINELLI PC d37db5a7-5167-4be5-9a98-180968b55c3e Q3 POLSINELLI PC 314911 TEVA PHARMACEUTICALS USA, INC. 2020 third_quarter PHA S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing and telehealth policies H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2020-10-15T17:11:45.260000-04:00
2510311 MCDERMOTT+ LLC bfd69f49-8ade-42be-ba28-98f437c9f12d Q3 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2020 third_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-16T08:20:02.117000-04:00
2510370 CARD & ASSOCIATES, LLC 006b6e06-916d-47fc-979d-43d0e5a4845d Q3 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2020 third_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing S 1895 Lower Healthcare Costs Act HR 2296 Fair Accountability and Innovative Research Drug Pricing Act HR 2376 Prescription Pricing for the People Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-16T09:17:19.930000-04:00
2510592 GOVERNMENT COUNSEL, LLC 8b803559-0a90-40d5-ab5b-d02294f41cf8 Q3 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2020 third_quarter PHA S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019; H.R. 4812-Ensuring Compliance Against Drug Diversion Act of 2019; H.R. 4806-Tthe Debarment Enforcement of Bad Actor Registrants Act of 2019; H.R. 3878-Block, Report And Suspend Suspicious Shipments Act of 2020; HR 7574-Strengthening America's Strategic National Stockpile Act of 2020. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-10-16T10:35:08.080000-04:00
2511119 REPUBLIC CONSULTING, LLC 57b6ec7b-e2ce-4c10-bd9e-350ca836d0ee Q3 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2020 third_quarter PHA Monitor Data and Science Policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-10-16T13:18:27.680000-04:00
2511390 BURRELL INTERNATIONAL GROUP LLC 9b637d25-9dc7-4598-8d61-5d0d0df4f084 Q3 BURRELL INTERNATIONAL GROUP LLC 401103483 ACER THERAPEUTICS 2020 third_quarter PHA COVID 19 therapeutics and Medical Countermeasures, Rare Disease and Re-purposed drugs HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-10-16T14:30:37.973000-04:00
2511472 CAPITOL COUNSEL LLC 6c70c870-e0f7-4dc0-9f22-5e1a7d9ec617 Q3 CAPITOL COUNSEL LLC 313715 VERTEX PHARMACEUTICALS INCORPORATED 2020 third_quarter PHA Monitoring and advocacy on matters related to the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-10-16T14:45:10.557000-04:00
2511572 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM d949897b-8b04-4afd-9acb-c0ace67423d0 Q3 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2020 third_quarter PHA Any bill(s), provision(s), or action(s) impacting the 340B Drug Discount Program and hospitals and health systems ability to provide access to these drugs for patients. Any bill(s) or provision(s) addressing high drug prices. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   57250 0 0 2020-10-16T15:08:42.583000-04:00
2511582 SAFEWAY INC. 477d1e44-3018-4e5d-9837-4a3485169a6c Q3 SAFEWAY INC. 300173 SAFEWAY 2020 third_quarter PHA CMS Medicaid Part D Final Rule, provisions related to DIR Fees H.R. 1034, S. 640 - Phair Pricing Act, all provisions H.R. 1614, S. 724 - John S. McCain Opioid Addiction Prevention Act, all provisions Issues related to pharmacist provider status S 2543 - Prescription Drug Pricing Reduction Act of 2019 - provisions related to Medicare Part D drug pricing. HHS Proposed Rule - Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees HOUSE OF REPRESENTATIVES,SENATE   90000 0 0 2020-10-16T15:09:43.717000-04:00
2511625 TARPLIN, DOWNS & YOUNG, LLC ee302a00-4131-4770-adae-686f5bdc951b Q3 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2020 third_quarter PHA Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting Importation of Prescription Drugs (H.R. 447, H.R. 478, H.R. 1478, S. 61, S. 97, S. 658, S. 844, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (H.R. 3878) Debarment Act (H.R. 4806) Ensuring Compliance Against Drug Diversion (H.R. 4812) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2020-10-16T15:17:57.550000-04:00
2511742 E3 STRATEGIC CONSULTING GROUP eb31f149-6d0b-4026-b330-fbd2bbc70496 Q3 E3 STRATEGIC CONSULTING GROUP 401104104 HEINZ STRATEGIES LLC (ON BEHALF OF PILMA) 2020 third_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-10-16T15:57:30.757000-04:00
2511743 E3 STRATEGIC CONSULTING GROUP fa6572cb-8d91-4bd0-9e6a-60c97e661f87 Q3 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2020 third_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-10-16T15:58:31.343000-04:00
2511799 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) f950f01f-5dd6-4049-99e9-11a3390c7702 Q3 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2020 third_quarter PHA Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) Debarment Act (HR 4806) Ensuring Compliance Against Drug Diversion (HR 4812) Suspicious Order Identification Act of 2019 (S. 2686, HR 4814) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   336505 0 0 2020-10-16T16:07:42.640000-04:00
2512113 340B HEALTH 2531cb51-99a2-4e7b-b2a7-cb5121c02fff Q3 340B HEALTH 316434 340B HEALTH 2020 third_quarter PHA The 340B Drug Pricing Program; FY 2021 L-HHS Appropriations; H.R. 4538, Closing Loopholes for Orphan Drug Act; S. 3631, Relief for Rural Providers During Emergencies Act; S. 4160, A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes; S. 4199, A bill to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes; H.R. 7838, To provide for certain temporary waivers with respect to the 340B drug discount program due to the COVID-19 public health emergency, and for other purposes. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   267118 0 0 2020-10-16T17:00:02.517000-04:00
2512114 PENN AVENUE PARTNERS 8a884644-0b74-4467-a659-31304f8ce498 Q3 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2020 third_quarter PHA Regulatory and legislative issues impacting Alkermes. S.3312: Crisis Stabilization and Community Reentry Act of 2020. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-16T17:01:03.057000-04:00
2512347 LINCOLN PARK GROUP L.L.C. fb5d62ab-3388-4dae-a9ab-bdc61a23a12e Q3 LINCOLN PARK GROUP L.L.C. 401104374 CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2020 third_quarter PHA Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-10-16T18:16:58.283000-04:00
2512480 BROWN & FORTUNATO, P.C. d4cc1c72-fcb7-404f-8c2c-c41e2aff132b Q3 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2020 third_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program. Issues related to H.R. 4945 - Safeguarding Medicare Access to Respiratory Therapy Act of 2019; H.R. 1865 - Further Consolidated Appropriations Act, 2020; H.R. 748 - CARES Act; H.R. 6201 - Family First Coronavirus Response Act. Issues related to H.R. 6218 and S. 3457 - The Preserving Medicare Access to Home Infusion Act. Centers For Medicare and Medicaid Services (CMS) 20000   0 0 2020-10-16T21:11:36.353000-04:00
2512524 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 20267e43-b643-40c9-a768-7020ddb36a57 Q3 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2020 third_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care, prescription drugs and generic drugs. Issues related to continuation of prescription drug access and testing during COVID crisis. Issues related to Medicare Part D rebates. HOUSE OF REPRESENTATIVES,SENATE 55000   0 0 2020-10-17T08:32:04.173000-04:00
2512539 BROYDRICK & ASSOCIATES 8b3ae8bc-d99f-41ad-998f-ccd03eb912ce Q3 BROYDRICK & ASSOCIATES 7268 EXELA PHARMA SCIENCES 2020 third_quarter PHA Drug shortages and FDA approval. USTR acceptance. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-10-17T09:39:10.910000-04:00
2512556 BROYDRICK & ASSOCIATES be61c632-c851-43dd-9d26-792da7ad74f7 Q3 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2020 third_quarter PHA Funding new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-10-17T09:57:18.553000-04:00
2512819 PUBLIC CITIZEN cb6701a2-6491-4ed0-a28b-f1bd306d95e8 Q3 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2020 third_quarter PHA H.R. 7296 (MMAPPP Act); H.R. 7288 (TRACK Act); Patents for Humanity Program Improvement Act; transparency for federally support covid R&D; covid-19 medicine pricing and access, Drug pricing, Covid 19 Medicine pricing, manufacture and access, HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE   100000 0 0 2020-10-17T14:48:09.177000-04:00
2513637 FORBES-TATE d16566d5-43ed-481e-9adb-0c8e3b3b22c8 Q3 FORBES-TATE 400976792 MERCK 2020 third_quarter PHA Issues related to prescription drug pricing, vaccines, animal health, and maternal health. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-18T15:19:31.293000-04:00
2513717 FORBES-TATE 55b9ff1c-3cb8-40cd-9301-1dcca29d5fe0 Q3 FORBES-TATE 400976792 PHRMA 2020 third_quarter PHA Issues pertaining to prescription drug pricing. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2020-10-18T16:15:50.400000-04:00
2514034 FOLEY & LARDNER LLP ff2614dd-9035-453a-ae9b-f4336cb913f0 Q3 FOLEY & LARDNER LLP 15042 BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) 2020 third_quarter PHA Market based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-10-18T22:04:25.330000-04:00
2514075 FOLEY & LARDNER LLP 83a3e55a-8654-4480-a8c2-a6a8e4325049 Q3 FOLEY & LARDNER LLP 15042 ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY 2020 third_quarter PHA FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2020-10-18T22:18:38.913000-04:00
2514102 FOLEY & LARDNER LLP b4ef9aac-56f0-44a4-96b7-4598b6f27508 Q3 FOLEY & LARDNER LLP 15042 FOUNDATION CONSUMER HEALTHCARE LLC 2020 third_quarter PHA legislation and regulations affecting marketing and commercialization of prescription and non-prescription drugs HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2020-10-18T22:25:45.383000-04:00
2514291 FREEDOMWORKS, INC. 9b31bdd7-73ac-4315-80b7-3573b7bc2c85 Q3 FREEDOMWORKS, INC. 9330 FREEDOMWORKS, INC. 2020 third_quarter PHA EO 13948 - Lowering Drug Prices by Putting America First; Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE,White House Office   220000 0 0 2020-10-19T03:07:26.807000-04:00
2514377 VAN SCOYOC ASSOCIATES be765bf7-8de1-4814-8396-7fe1c5c1f7e0 Q3 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2020 third_quarter PHA Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation Temperature monitoring technology for COVID-19 vaccines Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-10-19T06:03:48.630000-04:00
2514487 BALLARD PARTNERS c6e17a8c-f116-473c-9f60-86ac3a18eabb Q3 BALLARD PARTNERS 401104288 AVITA PHARMACY 2020 third_quarter PHA HRSA 340B Program Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),White House Office 30000   0 0 2020-10-19T07:36:11.397000-04:00
2514567 AMERICAN VETERINARY MEDICAL ASSOCIATION c222b726-3ba8-41cf-b17b-86b15191a9e6 Q3 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2020 third_quarter PHA GFI 256 FDA Compounding Guidance; Education, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Treasury, Dept of 240000   0 0 2020-10-19T08:35:25.593000-04:00
2514641 UC HEALTH 664e68df-ea2c-4955-a6bd-ee5b7c69f206 Q3 UC HEALTH 401103195 UC HEALTH 2020 third_quarter PHA 340B Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-10-19T09:05:43.447000-04:00
2514697 BUCHANAN INGERSOLL & ROONEY PC b48e5d29-3a73-42a8-9f5a-a3fa7371a3e6 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 AIM IMMUNOTECH INC. 2020 third_quarter PHA Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Navy, Dept of,SENATE 30000   0 0 2020-10-19T09:16:54.987000-04:00
2514862 TARPLIN, DOWNS & YOUNG, LLC a4d90054-7587-48f6-8319-84342ab33749 Q3 TARPLIN, DOWNS & YOUNG, LLC 304736 NOVO NORDISK INC. 2020 third_quarter PHA H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book Transparency Act of 2019; issues related to importation; issues related to 340B; H.R. 4244 MAGIC (Market Access for Generic Insulin Competition) Act to provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act) Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE 60000   0 0 2020-10-19T09:38:42.623000-04:00
2514937 FLYNN & ASSOCIATES, INC. d2febacb-7ee1-46b5-84fb-7532a0235c8d Q3 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2020 third_quarter PHA Drug Price controls Drug importation from Canada HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-10-19T09:51:00.510000-04:00
2514982 COVINGTON & BURLING LLP 59aaf6a0-b8f7-4e5d-99c0-fc85acfe3904 Q3 COVINGTON & BURLING LLP 11195 1776 PHARMACEUTICALS LLC 2020 third_quarter PHA Re-shoring production of essential medicine HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-10-19T09:55:08.747000-04:00
2515270 GENENTECH, INC 78dd0264-dd86-4446-a162-cd6b6b13b9e4 Q3 GENENTECH, INC 15920 GENENTECH INC 2020 third_quarter PHA S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office   2710000 0 0 2020-10-19T10:22:12.217000-04:00
2515293 POLITICAL CAPITAL, LLC e821f3fc-0340-41cb-97c1-691d93d0d5fe Q3 POLITICAL CAPITAL, LLC 401104260 MEDISCA INC 2020 third_quarter PHA Guidance documents, compounding pharmacy, appropriations language. Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-10-19T10:25:17.797000-04:00
2515319 POLITICAL CAPITAL, LLC 53976853-27af-479e-b3b2-3266bc374594 Q3 POLITICAL CAPITAL, LLC 401104260 STOKES PHARMACY 2020 third_quarter PHA Compounding Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2020-10-19T10:28:24.197000-04:00
2515536 ISEMAN & ASSOCIATES LLC 43fb3219-f1ed-4f85-9345-f8c1c920ed4f Q3 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2020 third_quarter PHA Monitoring biotech legislation; prescription drug prices HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2020-10-19T10:53:20.183000-04:00
2515558 BUCHANAN INGERSOLL & ROONEY PC 333d9a28-7a1a-4926-b434-f3a03d49c8b1 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 PHARMACEUTICAL ASSOCIATES, INC. 2020 third_quarter PHA Strategy development and implementation of company's federal government relations initiatives. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-10-19T10:55:28.077000-04:00
2515815 HOGAN LOVELLS US LLP c0da3886-c676-4140-a554-b9b3a164f2aa Q3 HOGAN LOVELLS US LLP 18422 ALVOGEN, PHARMA US, INC. 2020 third_quarter PHA Issues related to COVID-19 HOUSE OF REPRESENTATIVES,SENATE 220000   0 0 2020-10-19T11:19:19.653000-04:00
2516094 FAEGRE DRINKER BIDDLE & REATH LLP 28c5daa5-bb0d-407a-bf5e-ebe4974d316d Q3 FAEGRE DRINKER BIDDLE & REATH LLP 12631 ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL) 2020 third_quarter PHA Illicit prescription drug sales online; rouge internet drug sellers; dangers of counterfeit medicines; risks of drug importation on patient safety; domain name system accountability regarding COVID-19 frauds; WHOIS; Communications Decency Act, Section 230 reform Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 70000   0 0 2020-10-19T11:43:19.367000-04:00
2516138 FAEGRE DRINKER BIDDLE & REATH LLP d54cb81a-9c50-4855-9f17-558d3bca6eff Q3 FAEGRE DRINKER BIDDLE & REATH LLP 12631 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2020 third_quarter PHA Medication safety, pharmacy regulation, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R. 2482, S. 2074 - Mainstreaming Addiction Treatment Act; opposing prescription drug importation Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-10-19T11:46:32.347000-04:00
2516271 MR. VINCENT A. PANVINI b4890e41-a8be-47a3-86d9-6e5140b99739 Q3 MR. VINCENT A. PANVINI 401008845 PHRMA 2020 third_quarter PHA Position on Price Controls; patent Protections, Importation of Biopharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-10-19T11:57:02.237000-04:00
2516598 HANCE SCARBOROUGH 852b9d39-df62-43d9-a93e-c63513f9afd7 Q3 HANCE SCARBOROUGH 17443 PHRMA 2020 third_quarter PHA Patent reform regarding pharmaceutical research & products. SENATE 30000   0 0 2020-10-19T12:28:21.850000-04:00
2516854 HANCE SCARBOROUGH 4d87537d-b5de-402e-8bc1-d575d3dde800 Q3 HANCE SCARBOROUGH 17443 BOEHRINGER INGELHEIM USA CORPORATION 2020 third_quarter PHA Provide ongoing animal health policy monitoring, assessment, and research support. Telemedicine/telehealth legislation. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-10-19T12:48:25.917000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2445.394ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API